Overview

Founded in 1998, Structural GenomiX is a drug discovery company using genomics-driven, high-throughput structural biology to increase the efficiency and effectiveness of the drug discovery process. The company uses high-throughput X-ray crystallography, structural bioinformatics and chemistry to discover drugs intended to be more selective for their targets and result in fewer side effects and less toxicity.

Structural GenomiX's main programs are 3D-ID, a program of apo and co-complex structure determination for drug targets from bacterial pathogens; its SGX kinase program, to provide structural information on kinase targets and antitargets; its nuclear hormone receptor proteins program, to identify new ligands from these receptors; and its membrane protein program.

In April 2001, SGX acquired Prospect Genomics Inc., a high-throughput, computational drug discovery company.

Partners

In Janurary 2002, SGX entered into separate collaborations with Millennium Pharmaceuticals Inc. and Aventis Pharmaceuticals Inc. The company also has a collaboration with Graffinity Pharmaceuticals Design GmbH, as well as a $13 million, five-year collaboration with the Cystic Fibrosis Foundation to define the 3-dimensional structure of cystic fibrosis transmembrane regulator, a gene that can cause cystic fibrosis when defective.